Study finds dosing strategy may affect immunotherapy outcomes

(UT Southwestern Medical Center) Overweight cancer patients receiving immunotherapy treatments live more than twice as long as lighter patients, but only when dosing is weight-based, according to a study by cancer researchers at UT Southwestern Medical Center.